ERBB2 and ductal breast carcinoma in situ: One HER2 positive case showed substantial intra-tumor heterogeneity, yet the DCIS and invasive cells were represented in all the different subclones, possibly suggesting an early acquisition of invasive potential and subsequent parallel evolution.